Cargando…
Where do conventional OADs stand
The last two decades have witnessed unprecedented activity in the field of OADs with many new drugs becoming available. Concerns with OAD include cardiovascular safety, fear about hypoglycemia, weight gain etc. In this article we attempt to review OADs , sulfonylureas in particular, in the light of...
Autores principales: | Sahay, Rakesh Kumar, Nagesh, V. Sri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603040/ https://www.ncbi.nlm.nih.gov/pubmed/23565392 http://dx.doi.org/10.4103/2230-8210.104053 |
Ejemplares similares
-
Liquid biopsy for the assessment of adrenal cancer heterogeneity: where do we stand?
por: Perge, Pál, et al.
Publicado: (2022) -
The Advance Directives and Foregoing of Life Support: Where do we Stand Now?
por: Mani, Raj Kumar, et al.
Publicado: (2018) -
R(h)oads to microvesicles
por: Antonyak, Marc A., et al.
Publicado: (2012) -
Prolactin and cancer: Has the orphan finally found a home?
por: Sethi, Bipin Kumar, et al.
Publicado: (2012) -
Vaccines for COVID-19: Where do we stand in 2021?
por: Sharma, Ketaki, et al.
Publicado: (2021)